Previous 10 | Next 10 |
CLEVELAND, May 22, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference call and webcast to Wednesday, May 24, 2023, at 8:30 a.m. ET. The call was previously scheduled fo...
CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26 th Annual ...
2023-05-11 09:04:42 ET Abeona Therapeutics press release ( NASDAQ: ABEO ): Q1 GAAP EPS of -$0.54 beats by $0.07 . Cash, cash equivalents, restricted cash and short-term investments totaled $40.7 million as of March 31, 2023, compared to $52.5 million as of December 31,...
2023-05-11 08:44:10 ET Abeona Therapeutics ( NASDAQ: ABEO ) reported additional data from a phase 3 trial of EB-101 to treat recessive dystrophic epidermolysis bullosa (RDEB) at the International Societies for Investigative Dermatology (ISID) Meeting in Tokyo. Epidermolysis...
Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting Additional Phase 3 VIITAL™ study results presented at International Societies for Investigative Dermatology 2023 Meeting fur...
CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating its investigational EB-101 for recessive dystrophic epidermolysis bullosa (RDEB). The data...
2023-04-26 05:34:26 ET Summary Phase 3 VITAL study, using EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa, was successful in that both co-primary endpoints were met with statistical significance. A BLA submission of EB-101 for the treatment of ...
CLEVELAND, April 10, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26 th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023 in Los Angeles, CA. Accepted abstrac...
2023-03-29 08:10:01 ET Abeona Therapeutics press release ( NASDAQ: ABEO ): FY GAAP EPS of -$5.53 misses by $1.61 . Revenue of $1.41M (-53.0% Y/Y) misses by $0.91M . Cash, cash equivalents, restricted cash and short-term investments totaled $52.5 million as of D...
Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022 Advancing AAV-based gene therapy candidates toward IND studies in Stargardt Disease, X-linked Retinoschisis, and Autosomal Dominant Optic Atro...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...